Key points are not available for this paper at this time.
This comment discusses the use of PD-L1 as a biomarker to guide treatment decisions for metastatic melanoma.
Share your take
Add a clinician perspective alongside expert commentary.
Schmitt et al. (Mon,) studied this question.